HIV and the gut microbiota, partners in crime: Breaking the vicious cycle to unearth new therapeutic targets

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Vyboh, Kishanda ^a   Jenabian, Mohammad Ali ^a   Mehraj, Vikram ^a   Routy, Jean Pierre ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 7; PREBIOTIC AGENT; PROBIOTIC AGENT; SEVELAMER; TRYPTOPHAN;

DISEASE COURSE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; INTESTINE FLORA; PROTEIN EXPRESSION; REVIEW; ANIMAL; GASTROINTESTINAL TRACT; HIV INFECTIONS; IMMUNE SYSTEM; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; VIROLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INTESTINAL MUCOSA; METABOLIC NETWORKS AND PATHWAYS; TRYPTOPHAN;

EID: 84924366006     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/614127     Document Type: Review

References (84)

1. A. M. Caricilli, A. Castoldi, and N. O. Camara, "Intestinal barrier: a gentlemen's agreement between microbiota and immunity", The World Journal of Gastrointestinal Pathophysiology, vol. 5, no. 1, pp. 18-32, 2014.
2. D. M. Underhill and I. D. Iliev, "The mycobiota: interactions between commensal fungi and the host immune system", Nature Reviews Immunology, vol. 14, no. 6, pp. 405-416, 2014.
3. J. C. Clemente, L. K. Ursell, L. W. Parfrey, and R. Knight, "The impact of the gut microbiota on human health: an integrative view", Cell, vol. 148, no. 6, pp. 1258-1270, 2012.
4. I. Sekirov, S. L. Russell, L. C. M. Antunes, and B. B. Finlay, "Gut microbiota in health and disease", Physiological Reviews, vol. 90, no. 3, pp. 859-904, 2010.
5. S. F. Barefoot and T. R. Klaenhammer, "Detection and activity of lactacin B, a bacteriocin produced by Lactobacillus acidophilus", Applied and Environmental Microbiology, vol. 45, no. 6, pp. 1808-1815, 1983.
6. S. R. Konstantinov, H. Smidt, W. M. De Vos et al., "S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions", Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 49, pp. 19474-19479, 2008.
7. M. A. Von Schillde, G. Hörmannsperger, M. Weiher et al., "Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines", Cell Host and Microbe, vol. 11, no. 4, pp. 387-396, 2012.
8. H. Tjalsma, A. Boleij, J. R. Marchesi, and B. E. Dutilh, "A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects", Nature Reviews Microbiology, vol. 10, no. 8, pp. 575-582, 2012.
9. H. Zeng, D. L. Lazarova, and M. Bordonaro, "Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention", World Journal of Gastrointestinal Oncology, vol. 6, no. 2, pp. 41-51, 2014.
10. P. Ancuta, P. Monteiro, and R. P. Sekaly, "Th17 lineage commitment and HIV-1 pathogenesis", Current Opinion in HIV and AIDS, vol. 5, no. 2, pp. 158-165, 2010.
11. S. Viaud, R. Daillère, I. G. Boneca et al., "Gut microbiome and anticancer immune response: really hot Shit!", Cell Death and Differentiation, 2014.
12. R. Duarte, A. M. Silva, L. Q. Vieira, L. C. C. Afonso, and J. R. Nicoli, "Influence of normal microbiota on some aspects of the immune response during experimental infection with Trypanosoma cruzi in mice", Journal of Medical Microbiology, vol. 53, no. 8, pp. 741-748, 2004.
13. D. G. Souza, A. T. Vieira, A. C. Soares et al., "The essential role of the intestinal microbiota in facilitating acute inflammatory responses", Journal of Immunology, vol. 173, no. 6, pp. 4137-4146, 2004.
14. M. Kane, L. K. Case, K. Kopaskie et al., "Successful transmission of a retrovirus depends on the commensal microbiota", Science, vol. 334, no. 6053, pp. 245-249, 2011.
15. S. K. Kuss, G. T. Best, C. A. Etheredge et al., "Intestinal microbiota promote enteric virus replication and systemic pathogenesis", Science, vol. 334, no. 6053, pp. 249-252, 2011.
16. T.-W. Chun, D. C. Nickle, J. S. Justement et al., "Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy", Journal of Infectious Diseases, vol. 197, no. 5, pp. 714-720, 2008.
17. + mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection", Journal of Virology, vol. 75, no. 18, pp. 8390-8399, 2001.
18. + T cells in multiple tissues during acute SIV infection", Nature, vol. 434, no. 7037, pp. 1093-1097, 2005.
19. J. Fan, H. Z. Bass, and J. L. Fahey, "Elevated IFN-γ and decreased IL-2 gene expression are associated with HIVinfection", Journal of Immunology, vol. 151, no. 9, pp. 5031-5040, 1993.
20. E. C. Breen, A. R. Rezai, K. Nakajima et al., "Infection with HIV is associated with elevated IL-6 levels and production", Journal of Immunology, vol. 144, no. 2, pp. 480-484, 1990.
21. + T-cell counts in HIV controller patients", AIDS, vol. 28, no. 4, pp. 467-476, 2014.
22. D. Favre, J. Mold, P. W. Hunt et al., "Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease", Science Translational Medicine, vol. 2, no. 32, article 32ra36, 2010.
23. L. Houzet, M. L. Yeung, V. De Lame, D. Desai, S. M. Smith, and K.-T. Jeang, "Micro RNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals", Retrovirology, vol. 5, article 118, 2008.
24. N. Singh, E. A. Shirdel, L. Waldron, R. H. Zhang, I. Jurisica, and E. M. Comelli, "The murine caecal micro RNA signature depends on the presence of the endogenous microbiota", International Journal of Biological Sciences, vol. 8, no. 2, pp. 171-186, 2011.
25. G. Dalmasso, H. T. T. Nguyen, Y. Yan et al., "Microbiota modulate host gene expression via micrornas", PLoS ONE, vol. 6, no. 4, Article ID e19293, 2011.
26. A. Nazli, O. Chan, W. N. Dobson-Belaire et al., "Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation", PLoS Pathogens, vol. 6, no. 4, Article ID e1000852, 2010.
27. U. Hofer and R. F. Speck, "Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection", Seminars in Immunopathology, vol. 31, no. 2, pp. 257-266, 2009.
28. + Tcell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy", Journal of Virology, vol. 77, no. 21, pp. 11708-11717, 2003.
29. M.-A. Jenabian, M. Patel, I. Kema et al., "Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers", PLoS ONE, vol. 8, no. 10, Article IDe 78146, 2013.
30. P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young, "Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation", The Journal of Immunology, vol. 164, no. 7, pp. 3596-3599, 2000.
31. D. H. Munn, E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor, "Inhibition of T cell proliferation by macrophage tryptophan catabolism", The Journal of Experimental Medicine, vol. 189, no. 9, pp. 1363-1372, 1999.
32. A. J. Muller, M. D. Sharma, P. R. Chandler et al., "Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase", Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 44, pp. 17073-17078, 2008.
33. H. Soliman, M. Mediavilla-Varela, and S. Antonia, "Indoleamine 2, 3-dioxygenase: is it an immune suppressor?" Cancer Journal, vol. 16, no. 4, pp. 354-359, 2010.
34. J. R. Moffett and M. A. Namboodiri, "Tryptophan and the immune response", Immunology and Cell Biology, vol. 81, no. 4, pp. 247-265, 2003.
35. C. A. Opitz, U. M. Litzenburger, F. Sahm et al., "An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor", Nature, vol. 478, no. 7368, pp. 197-203, 2011.
36. L. F. Doherty, H. E. Kwon, and H. S. Taylor, "Regulation of tryptophan 2, 3-dioxygenase by HOXA10 enhances embryo viability through serotonin signaling", American Journal of Physiology: Endocrinology and Metabolism, vol. 300, no. 1, pp. E86-E93, 2011.
37. S. J. Thackray, C. G. Mowat, and S. K. Chapman, "Exploring the mechanism of tryptophan 2, 3-dioxygenase", Biochemical Society Transactions, vol. 36, part 6, pp. 1120-1123, 2008.
38. J. Godin-Ethier, L.-A. Hanafi, C. A. Piccirillo, and R. Lapointe, "Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives", Clinical Cancer Research, vol. 17, no. 22, pp. 6985-6991, 2011.
39. R. Zangerle, B. Widner, G. Quirchmair, G. Neurauter, M. Sarcletti, and D. Fuchs, "Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection", Clinical Immunology, vol. 104, no. 3, pp. 242-247, 2002.
40. + T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells", Blood, vol. 109, no. 8, pp. 3351-3359, 2007.
41. G. Frumento, R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara, "Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase", The Journal of Experimental Medicine, vol. 196, no. 4, pp. 459-468, 2002.
42. G. J. Guillemin, S. J. Kerr, and B. J. Brew, "Involvement of quinolinic acid in aids dementia complex", Neurotoxicity Research, vol. 7, no. 1-2, pp. 103-123, 2005.
43. D. J. Chung, M. Rossi, E. Romano et al., "Indoleamine 2, 3-dioxygenase-expressingmature humanmonocyte-derived dendritic cells expand potent autologous regulatory T cells", Blood, vol. 114, no. 3, pp. 555-563, 2009.
44. R. Planès and E. Bahraoui, "HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation", PLoS ONE, vol. 8, no. 9, Article ID e74551, 2013.
45. I. Vujkovic-Cvijin, R. M. Dunham, S. Iwai et al., "Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism", Science Translational Medicine, vol. 5, no. 193, Article ID 193ra91, 2013.
46. J. M. Shaw, P. W. Hunt, J. W. Critchfield et al., "Increased frequency of regulatory t cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers", Journal of Virology, vol. 85, no. 21, pp. 11422-11434, 2011.
47. L. Alcalá, M. J. Ruiz-Serrano, J. Cosín, F. García-Garrote, A. Ortega, and E. Bouza, "Disseminated infection due to Mycobacterium simiae in an AIDS patient: case report and review", Clinical Microbiology and Infection, vol. 5, no. 5, pp. 294-296, 1999.
48. D. N. Frank, A. L. St. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases", Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13780-13785, 2007.
49. C. A. Lozupone, M. E. Rhodes, C. P. Neff, A. P. Fontenot, T. B. Campbell, and B. E. Palmer, "HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy", Gut Microbes, vol. 5, no. 4, pp. 562-570, 2014.
50. J. Pérez-Santiago, S. Gianella, M. Massanella et al., "Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection", AIDS, vol. 27, no. 12, pp. 1921-1931, 2013.
51. T. Zelante, R. Iannitti, C. Cunha et al., "Tryptophan catabolites frommicrobiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22", Immunity, vol. 39, no. 2, pp. 372-385, 2013.
52. M. L. Balmer, E. Slack, A. De Gottardi et al., "The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota", Science Translational Medicine, vol. 6, no. 237, Article ID237ra66, 2014.
53. S. G. Deeks, R. Tracy, and D. C. Douek, "Systemic effects of inflammation on health during chronic HIV infection", Immunity, vol. 39, no. 4, pp. 633-645, 2013.
54. F. T. Hufert, J. Schmitz, M. Schreiber, H. Schmitz, P. Racz, and D. D. Von Laer, "Human Kupffer cells infected with HIV-1 in vivo", Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 7, pp. 772-777, 1993.
55. P. Tuma, J. Medrano, S. Resino et al., "Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy", Antiviral Therapy, vol. 15, no. 6, pp. 881-886, 2010.
56. L. Peters, J. Neuhaus, D. Duprez et al., "Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study", Journal of Clinical Virology, vol. 60, no. 3, pp. 295-300, 2014.
57. M. F. Chevalier, G. Petitjean, C. Dunyach-Rémy et al., "The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation", PLoS Pathogens, vol. 9, no. 6, Article ID e1003453, 2013.
58. S. Abdurahman, B. Barqasho, P. Nowak et al., "Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden", Journal of the International AIDS Society, vol. 17, Article ID 18841, 2014.
59. M. Romero-Sánchez, A. González-Serna, Y. M. Pacheco et al., "Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers", Journal of Infection, vol. 65, no. 5, pp. 431-438, 2012.
60. Y. Chen, S.-L. Hwang, V. S. F. Chan et al., "Binding of HIV-1 gp120 to DC-SIGN promotes ASK-1-dependent activationinduced apoptosis of human dendritic cells", PLoS Pathogens, vol. 9, no. 1, Article IDe 1003100, 2013.
61. M. A. Jenabian, M. Patel, I. Kema et al., "Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection", Clinical & Experimental Immunology, vol. 178, no. 1, pp. 102-111, 2014.
62. + T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy", The Journal of Infectious Diseases, vol. 210, no. 3, pp. 383-391, 2014.
63. P. Martinez, A. C. Tsai, C. Muzoora et al., "Reversal of the kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected ugandans", Journal of Acquired Immune Deficiency Syndromes, vol. 65, no. 4, pp. 456-462, 2014.
64. S. F. Assimakopoulos, D. Dimitropoulou, M. Marangos, and C. A. Gogos, "Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies", Infection, 2014.
65. R. Owe-Young, N. L. Webster, M. Mukhtar et al., "Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance & neurotoxicity", Journal of Neurochemistry, vol. 105, no. 4, pp. 1346-1357, 2008.
66. X. Fu, M. A. Lawson, K. W. Kelley, and R. Dantzer, "HIV-1 Tat activates indoleamine 2, 3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner", Journal of Neuroinflammation, vol. 8, article 88, 2011.
67. J. A. Ciesla and J. E. Roberts, "Meta-analysis of the relationship between HIV infection and risk for depressive disorders", The American Journal of Psychiatry, vol. 158, no. 5, pp. 725-730, 2001.
68. A. M. Sardar and G. P. Reynolds, "Frontal cortex indoleamine-2, 3-dioxygenase activity is increased in HIV-1-associated dementia", Neuroscience Letters, vol. 187, no. 1, pp. 9-12, 1995.
69. N. Le Floc'h, W. Otten, and E. Merlot, "Tryptophanmetabolism, from nutrition to potential therapeutic applications", Amino Acids, vol. 41, no. 5, pp. 1195-1205, 2011.
70. W. Wu, J. A. Nicolazzo, L. Wen et al., "Expression of tryptophan 2, 3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain", PLoS ONE, vol. 8, no. 4, Article ID e59749, 2013.
71. A. W. Corona, D. M. Norden, J. P. Skendelas et al., "Indoleamine 2, 3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX3CR1)-deficient mice", Brain, Behavior, and Immunity, vol. 31, pp. 134-142, 2013.
72. R. Potula, L. Poluektova, B. Knipe et al., "Inhibition of indoleamine 2, 3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis", Blood, vol. 106, no. 7, pp. 2382-2390, 2005.
73. A. Boasso, M. Vaccari, D. Fuchs et al., "Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques", The Journal of Immunology, vol. 182, no. 7, pp. 4313-4320, 2009.
74. R. M. Dunham, S. N. Gordon, M. Vaccari et al., "Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesusmacaque: a pilot study testing inhibition of indoleamine 2, 3-dioxygenase", AIDS Research and Human Retroviruses, vol. 29, no. 2, pp. 207-214, 2013.
75. X. D. Yao, R. W. Omange, B. M. Henrick et al., "Acting locally: innate mucosal immunity in resistance to HIV-1 infection in Kenyan commercial sex workers", Mucosal Immunology, vol. 7, no. 2, pp. 268-279, 2014.
76. E. M. Songok, M. Luo, B. Liang et al., "Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state", PLoS ONE, vol. 7, no. 1, Article ID e30048, 2012.
77. P. R. Marteau, M. De Vrese, C. J. Cellier, and J. Schrezenmeir, "Protection from gastrointestinal diseases with the use of probiotics", The American Journal of Clinical Nutrition, vol. 73, no. 2, supplement, pp. 430S-436S, 2001.
78. N. R. Klatt, L. A. Canary, X. Sun et al., "Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques", The Journal of Clinical Investigation, vol. 123, no. 2, pp. 903-907, 2013.
79. S. Cunningham-Rundles, S. Ahrné, R. Johann-Liang et al., "Effect of probiotic bacteria on microbial host defense, growth and immune function in human immunodeficiency virus type-1 infection", Nutrients, vol. 3, no. 12, pp. 1042-1070, 2011.
80. M. C. Perianayagam and B. L. Jaber, "Endotoxin-binding affinity of sevelamer hydrochloride", American Journal of Nephrology, vol. 28, no. 5, pp. 802-807, 2008.
81. J. Kristoff, G. Haret-Richter, D. Ma et al., "Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication", The Journal of Clinical Investigation, vol. 124, no. 6, pp. 2802-2806, 2014.
82. N. G. Sandler, "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection", The Journal of Infectious Diseases, vol. 210, no. 10, pp. 1549-1554, 2014.
83. N. Kamada and G. Núñez, "Role of the gut microbiota in the development and function of lymphoid cells", Journal of Immunology, vol. 190, no. 4, pp. 1389-1395, 2013.
84. I. Sereti, J. D. Estes, W. L. Thompson et al., "Decreases in Colonic and Systemic Inflammation in Chronic HIV Infection after IL-7 Administration", PLoS Pathogens, vol. 10, no. 1, Article ID e1003890, 2014.